WIPRO
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), en førende global virksomhed inden for informationsteknologi, konsulentvirksomhed og forretningsprocesser annoncerede i dag udnævnelsen af Pierre Bruno som administrerende direktør, Europa.
I denne rolle vil Bruno lede Wipro’s forretning i seks forskellige regioner på tværs af Europa. Denne udnævnelse, er en dristig indikation af virksomhedens fortsatte investering og fokus på det europæiske marked, som bygger på Wipros fremdrift i hele regionen i de seneste år.
“Pierre har mere end 25 års erfaring inden for IT-infrastruktur, konsulent og servicesektoren. Han har leder virksomheder i både hypervækstmiljøer og inden for teknologi transformation. Med hans erfaring i ledelse af store teams er han godt positioneret til at føre Wipros vækstrejse videre i Europa,” sagde Thierry Delaporte, CEO & MD, Wipro Limited.
“Jeg er begejstret for muligheden for at lede Wipro’s aktiviteter på det europæiske marked, der byder på fantastiske muligheder for vækst. Jeg ser frem til at videreudvikle samt fremme vores engagement over for vores europæiske kunder, når de navigerer i deres forretningstransformation og fortsætter med at udvikle sig i en digital verden,” sagde Pierre Bruno , Administrerende direktør, Europa .
Bruno kommer til Wipro fra DXC Technology, hvor han var vicepræsident og administrerende direktør for Sydeuropa, ansvarlig for alle dele af forretningen, herunder rådgivning, integration, apps, cloud og cybersikkerhed. Bruno arbejdede også for Dell i 14 år i flere roller i Asien, Stillehavsområdet, Japan og EMEA. Han spillede en central rolle i Dells transformation fra at sælge hardware til at blive en vigtig aktør inden for levering af infrastrukturløsninger.
Bruno har en kandidatgrad i forretningsadministration (MBA) med hovedfag i Marketing og økonometri fra HEC Graduate School i Paris. Han har også en kandidatgrad i bioteknik.
Wipro’s forpligtelse i Europa
Wipro’s europæiske tilstedeværelse omfatter seks regioner, bestående af Storbritannien og Irland, Tyskland, Schweiz, Norden, Benelux og Sydeuropa, samt tre near-shore leverancecentre og omfatter en bred vifte af betydelige kunder på tværs af brancher, hvoraf mange bliver supporteret af Wipro på deres teknologiste vækst samt transformationsrejse..
Nogle af de seneste aftaler i Europa omfatter
- En vigtig strategisk digital og IT-partnerskabsaftale med METRO AG, en førende global grossistvirksomhed.
- Et engagement med den Finland-baserede producent af ren energi Fortum for at hjælpe med at opgradere applikationslandskabet samt tilhørende serviceintegration,.
- En flerårig global aftale om automotive engineering services med den italienske bilgigant Marelli.
- I Tyskland arbejder vi sammen med Telefónica Germany/O2 og dets bredere økosystem til at transformere deres forretningssupportsystemer og tilhørende kvalitetssikring for at sikre en optimal kundeoplevelse og vækst i B2B-markedssegmentet.
- En strategisk, flerårig infrastruktur’s modernisering og digital transformations services fra det tyskbaserede energiselskab E.ON.
Om Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) er en førende global virksomhed inden for informationsteknologi, rådgivning og forretningsprocesser. Vi udnytter styrken af kognitive computing, hyper-automatisering, robotteknologi, cloud , analytics og nye teknologier til at hjælpe vores kunder med at tilpasse sig den digitale verden og gøre successfulde. En virksomhed, der er anerkendt globalt for sin omfattende portefølje af services, stærkt engagement i bæredygtighed samt virksomhedsetik , vi har over 190.000 dedikerede medarbejdere, der betjener vores kunder på seks kontinenter. Sammen kommer vi med nye ideer samt udvikler og skaber en bedre og dristig ny fremtid.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov
. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210310005602/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 07:39:00 CET | Press release
Vinmec Health System attracts international patients to Vietnam for treatment Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi
METI will hold GGX Finance Summit27.10.2025 07:30:00 CET | Press release
On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth. Outline of GGX Finance Summit Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00) Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation)
NITMX, Ant International and Krungthai Bank Expand Payment Connectivity Between Thailand and China via PromptPay27.10.2025 04:37:00 CET | Press release
The parties will promote inbound payments via PromptPay and Alipay, an Alipay+ e-wallet partner, enabling more convenience for Chinese travellersPartnership builds on Alipay+’s efforts to support the tourism industry in Thailand and enable local merchants to connect with travellers from China and beyond Under the guidance of the Bank of Thailand, Ant International, a leading global digital payment, digitisation and financial technology provider and National ITMX will partner to enhance and promote payments connectivity via PromptPay, between Thai merchants and Chinese consumers, which will be launched soon. Krungthai Bank will be the settlement bank for this cross-border QR partnership. In the initial phase, Chinese travellers to Thailand can use Alipay, an Alipay+ e-wallet partner, to make QR payment at millions of local merchants by scanning the PromptPay QR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026429360/en/
Helical Fusion Achieves Milestone Toward Commercial Fusion Energy, Advancing to Integrated Demonstration Device27.10.2025 04:00:00 CET | Press release
— World’s First Performance Test of a High-Temperature Superconducting Coil Under Conditions Replicating the Magnetic Environment Inside a Fusion Device — Helical Fusion Co., Ltd., a world-leading developer of the Helical Stellarator, has completed a critical performance test of a high-temperature superconducting (HTS) coil—a core component of commercial fusion reactors. The company has now commenced manufacturing and construction of its integrated demonstration device, Helix HARUKA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026597002/en/ Helical Fusion members celebrating the successful HTS test with an “HTS Graduation!” sign and graduation caps Watch the key points of this release in a 2-minute video: https://youtu.be/UhgQHfKtvow Helical Fusion is the only company in the world building upon expertise in the Helical Stellarator approach, accumulated for more than 60 years at national institutes and national universi
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release
Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum